Literature DB >> 2956079

[Treatment of tumor hypercalcemia with clodronate. Effect on parathormone and calcitriol].

S H Scharla, H W Minne, P Sattar, U Mende, E Blind, H Schmidt-Gayk, C Wüster, T Ho, R Ziegler.   

Abstract

Clodronate (dichlormethylene diphosphonate) was administered to 21 patients with hypercalcemia due to malignant tumor. The drug was initially given intravenously, then orally. In 20 patients the serum calcium level had been reduced to the normal range within one week of the start of treatment (from 3.3 +/- 0.5 mmol/l to 2.4 +/- 0.3 mmol/l). With oral administration there was a renewed rise in calcium levels in some patients, which had to be treated with higher oral doses or intravenous administration. Parallel with the reduction in calcium levels there was an improvement in the originally impaired renal function. The serum level of intact parathormone(1-84) and 1.25-dihydroxy-vitamin-D3 (calcitriol) rose significantly from usually lowered initial levels. There was a non-linear inverse correlation between parathormone and calcium. No side effects were noted, even after long-term administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956079     DOI: 10.1055/s-2008-1068205

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  [Pamidronate in the treatment of tumor-associated hypercalcemia].

Authors:  M Pecherstorfer; S Janisch; C Marosi; C Wogritsch; C Bosse; W Schratzberger; E Gerber; A Fortelny; R Lenzhofer; H Rainer
Journal:  Klin Wochenschr       Date:  1991-10-02

4.  Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease.

Authors:  Nina V Lyubimova; Nikolay E Kushlinsky; Michail R Lichinitser; Karl Schlosser
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.